Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 277

1.

The AQARA Principle: Proposing Standard Requirements for Radionuclide-Based Images in Medical Journals.

Weber WA, Bengel FM, Blasberg RG.

J Nucl Med. 2020 Jan;61(1):1-2. doi: 10.2967/jnumed.119.240523. No abstract available.

PMID:
31896724
2.

Quantitative and Qualitative Analyses of Biodistribution and PET Image Quality of Novel Radiohybrid PSMA, 18F- rhPSMA-7, in Patients with Prostate Cancer.

Oh SW, Wurzer A, Teoh EJ, Oh S, Langbein T, Krönke M, Herz M, Kropf S, Wester HJ, Weber WA, Eiber M.

J Nucl Med. 2019 Dec 13. pii: jnumed.119.234609. doi: 10.2967/jnumed.119.234609. [Epub ahead of print]

PMID:
31836686
3.

18F-rhPSMA-7 positron emission tomography for the detection of biochemical recurrence of prostate cancer following radical prostatectomy.

Eiber M, Krönke M, Wurzer A, Ulbrich L, Jooß L, Maurer T, Horn T, Schiller K, Langbein T, Buschner G, Wester HJ, Weber WA.

J Nucl Med. 2019 Dec 13. pii: jnumed.119.234914. doi: 10.2967/jnumed.119.234914. [Epub ahead of print]

PMID:
31836682
4.

Histologically-confirmed diagnostic efficacy of 18F-rhPSMA-7 positron emission tomography for N-staging of patients with primary high risk prostate cancer.

Krönke M, Wurzer A, Schwamborn K, Ulbrich L, Jooß L, Maurer T, Horn T, Rauscher I, Haller B, Herz M, Wester HJ, Weber WA, Eiber M.

J Nucl Med. 2019 Dec 13. pii: jnumed.119.234906. doi: 10.2967/jnumed.119.234906. [Epub ahead of print]

PMID:
31836681
5.

Correlative analyses between tissue-based hypoxia biomarkers and hypoxia PET imaging in head and neck cancer patients during radiochemotherapy-results from a prospective trial.

Nicolay NH, Wiedenmann N, Mix M, Weber WA, Werner M, Grosu AL, Kayser G.

Eur J Nucl Med Mol Imaging. 2019 Dec 7. doi: 10.1007/s00259-019-04598-9. [Epub ahead of print]

PMID:
31811344
6.

Evaluation of SUV normalized by lean body mass (SUL) in 68Ga-PSMA11 PET/CT: a bi-centric analysis.

Gafita A, Calais J, Franz C, Rauscher I, Wang H, Roberstson A, Czernin J, Weber WA, Eiber M.

EJNMMI Res. 2019 Dec 2;9(1):103. doi: 10.1186/s13550-019-0572-z.

7.

Retooling a Blood-Based Biomarker: Phase I Assessment of the High-Affinity CA19-9 Antibody HuMab-5B1 for Immuno-PET Imaging of Pancreatic Cancer.

Lohrmann C, O'Reilly EM, O'Donoghue JA, Pandit-Taskar N, Carrasquillo JA, Lyashchenko SK, Ruan S, Teng R, Scholz W, Maffuid PW, Lewis JS, Weber WA.

Clin Cancer Res. 2019 Dec 1;25(23):7014-7023. doi: 10.1158/1078-0432.CCR-18-3667. Epub 2019 Sep 20.

PMID:
31540979
8.

Correction to: 18F-Fluciclovine (18F-FACBC) PET imaging of recurrent brain tumors.

Michaud L, Beattie BJ, Akhurst T, Dunphy M, Zanzonico P, Finn R, Mauguen A, Schöder H, Weber WA, Lassman AB, Blasberg R.

Eur J Nucl Med Mol Imaging. 2020 Jan;47(1):4. doi: 10.1007/s00259-019-04514-1.

9.

Driving the Future of Nuclear Medicine.

Herrmann K, Veit-Haibach P, Weber WA.

J Nucl Med. 2019 Sep;60(Suppl 2):1S-2S. doi: 10.2967/jnumed.119.232264. No abstract available.

PMID:
31481584
10.

Future of Theranostics: An Outlook on Precision Oncology in Nuclear Medicine.

Langbein T, Weber WA, Eiber M.

J Nucl Med. 2019 Sep;60(Suppl 2):13S-19S. doi: 10.2967/jnumed.118.220566.

PMID:
31481583
11.

Phase I Trial of Well-Differentiated Neuroendocrine Tumors (NETs) with Radiolabeled Somatostatin Antagonist 177Lu-Satoreotide Tetraxetan.

Reidy-Lagunes D, Pandit-Taskar N, O'Donoghue JA, Krebs S, Staton KD, Lyashchenko SK, Lewis JS, Raj N, Gönen M, Lohrmann C, Bodei L, Weber WA.

Clin Cancer Res. 2019 Dec 1;25(23):6939-6947. doi: 10.1158/1078-0432.CCR-19-1026. Epub 2019 Aug 22.

PMID:
31439583
12.

18F-Fluciclovine (18F-FACBC) PET imaging of recurrent brain tumors.

Michaud L, Beattie BJ, Akhurst T, Dunphy M, Zanzonico P, Finn R, Mauguen A, Schöder H, Weber WA, Lassman AB, Blasberg R.

Eur J Nucl Med Mol Imaging. 2019 Aug 15. doi: 10.1007/s00259-019-04433-1. [Epub ahead of print] Erratum in: Eur J Nucl Med Mol Imaging. 2019 Sep 7;:.

PMID:
31418054
13.

Molecular Imaging of Fibroblast Activity After Myocardial Infarction Using a 68Ga-Labeled Fibroblast Activation Protein Inhibitor, FAPI-04.

Varasteh Z, Mohanta S, Robu S, Braeuer M, Li Y, Omidvari N, Topping G, Sun T, Nekolla SG, Richter A, Weber C, Habenicht A, Haberkorn UA, Weber WA.

J Nucl Med. 2019 Dec;60(12):1743-1749. doi: 10.2967/jnumed.119.226993. Epub 2019 Aug 12.

PMID:
31405922
14.

Can the injected dose be reduced in 68Ga-PSMA-11 PET/CT maintaining high image quality for lesion detection?

Rauscher I, Fendler WP, Hope T, Quon A, Nekolla SG, Calais J, Richter A, Haller B, Herrmann K, Weber WA, Czernin J, Eiber M.

J Nucl Med. 2019 Jul 19. pii: jnumed.119.227207. doi: 10.2967/jnumed.119.227207. [Epub ahead of print]

PMID:
31324710
15.

Exceptional 4-year response to 177Lu-PSMA radioligand therapy in metastatic castration-resistant prostate cancer.

Gafita A, Wang H, Tauber R, D'Alessandria C, Weber WA, Eiber M.

Eur J Nucl Med Mol Imaging. 2019 Sep;46(10):2212-2213. doi: 10.1007/s00259-019-04410-8. Epub 2019 Jul 4. No abstract available.

PMID:
31273434
16.

89Zr-Immuno-PET: Toward a Noninvasive Clinical Tool to Measure Target Engagement of Therapeutic Antibodies In Vivo.

Jauw YWS, O'Donoghue JA, Zijlstra JM, Hoekstra OS, Menke-van der Houven van Oordt CW, Morschhauser F, Carrasquillo JA, Zweegman S, Pandit-Taskar N, Lammertsma AA, van Dongen GAMS, Boellaard R, Weber WA, Huisman MC.

J Nucl Med. 2019 Dec;60(12):1825-1832. doi: 10.2967/jnumed.118.224568. Epub 2019 May 30.

PMID:
31147401
17.

Neuroimaging for Radiation Therapy of Brain Tumors.

Popp I, Weber WA, Combs SE, Yuh WTC, Grosu AL.

Top Magn Reson Imaging. 2019 Apr;28(2):63-71. doi: 10.1097/RMR.0000000000000198. Review.

PMID:
31022049
18.

Prospective Study of the Radiolabeled GRPR Antagonist BAY86-7548 for Positron Emission Tomography/Computed Tomography Imaging of Newly Diagnosed Prostate Cancer.

Touijer KA, Michaud L, Alvarez HAV, Gopalan A, Kossatz S, Gonen M, Beattie B, Sandler I, Lyaschenko S, Eastham JA, Scardino PT, Hricak H, Weber WA.

Eur Urol Oncol. 2019 Mar;2(2):166-173. doi: 10.1016/j.euo.2018.08.011. Epub 2018 Sep 22.

PMID:
31017093
19.

Longitudinal proton spectroscopy study of the prefrontal cortex in youth at risk for bipolar disorder before and after their first mood episode.

Nery FG, Weber WA, Blom TJ, Welge J, Patino LR, Strawn JR, Chu WJ, Adler CM, Komoroski RA, Strakowski SM, DelBello MP.

Bipolar Disord. 2019 Jun;21(4):330-341. doi: 10.1111/bdi.12770. Epub 2019 Mar 28.

PMID:
30864200
20.

qPSMA: Semiautomatic Software for Whole-Body Tumor Burden Assessment in Prostate Cancer Using 68Ga-PSMA11 PET/CT.

Gafita A, Bieth M, Krönke M, Tetteh G, Navarro F, Wang H, Günther E, Menze B, Weber WA, Eiber M.

J Nucl Med. 2019 Sep;60(9):1277-1283. doi: 10.2967/jnumed.118.224055. Epub 2019 Mar 8.

PMID:
30850484
21.

Pitfalls in Ga-68-PSMA-PET/CT: incidental finding of parathyroid adenoma.

Pfob CH, Karimov I, Jesinghaus M, Novotny A, Weber WA, Eiber M, Feuerecker B.

Eur J Nucl Med Mol Imaging. 2019 Apr;46(4):1041. doi: 10.1007/s00259-018-4239-1. Epub 2018 Dec 19. No abstract available.

PMID:
30569188
22.

Consensus on molecular imaging and theranostics in prostate cancer.

Fanti S, Minozzi S, Antoch G, Banks I, Briganti A, Carrio I, Chiti A, Clarke N, Eiber M, De Bono J, Fizazi K, Gillessen S, Gledhill S, Haberkorn U, Herrmann K, Hicks RJ, Lecouvet F, Montironi R, Ost P, O'Sullivan JM, Padhani AR, Schalken JA, Scher HI, Tombal B, van Moorselaar RJA, Van Poppel H, Vargas HA, Walz J, Weber WA, Wester HJ, Oyen WJG.

Lancet Oncol. 2018 Dec;19(12):e696-e708. doi: 10.1016/S1470-2045(18)30604-1.

PMID:
30507436
23.

Prognostic value of baseline metabolic tumor volume measured on 18F-fluorodeoxyglucose positron emission tomography/computed tomography in melanoma patients treated with ipilimumab therapy.

Ito K, Schöder H, Teng R, Humm JL, Ni A, Wolchok JD, Weber WA.

Eur J Nucl Med Mol Imaging. 2019 Apr;46(4):930-939. doi: 10.1007/s00259-018-4211-0. Epub 2018 Nov 28.

PMID:
30488098
24.

Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with 177Lu-PSMA-I&T in Metastatic Castration-resistant Prostate Cancer.

Heck MM, Tauber R, Schwaiger S, Retz M, D'Alessandria C, Maurer T, Gafita A, Wester HJ, Gschwend JE, Weber WA, Schwaiger M, Knorr K, Eiber M.

Eur Urol. 2019 Jun;75(6):920-926. doi: 10.1016/j.eururo.2018.11.016. Epub 2018 Nov 22.

PMID:
30473431
25.

EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2-Amplified Esophagogastric Cancer.

Sanchez-Vega F, Hechtman JF, Castel P, Ku GY, Tuvy Y, Won H, Fong CJ, Bouvier N, Nanjangud GJ, Soong J, Vakiani E, Schattner M, Kelsen DP, Lefkowitz RA, Brown K, Lacouture ME, Capanu M, Mattar M, Qeriqi B, Cecchi F, Tian Y, Hembrough T, Nagy RJ, Lanman RB, Larson SM, Pandit-Taskar N, Schöder H, Iacobuzio-Donahue CA, Ilson DH, Weber WA, Berger MF, de Stanchina E, Taylor BS, Lewis JS, Solit DB, Carrasquillo JA, Scaltriti M, Schultz N, Janjigian YY.

Cancer Discov. 2019 Feb;9(2):199-209. doi: 10.1158/2159-8290.CD-18-0598. Epub 2018 Nov 21.

PMID:
30463996
26.

Early Experience of Rechallenge 177Lu-PSMA Radioligand Therapy After an Initial Good Response in Patients with Advanced Prostate Cancer.

Gafita A, Rauscher I, Retz M, Knorr K, Heck M, Wester HJ, D'Alessandria C, Weber WA, Eiber M, Tauber R.

J Nucl Med. 2019 May;60(5):644-648. doi: 10.2967/jnumed.118.215715. Epub 2018 Nov 15.

PMID:
30442756
27.

18F-FDG PET/CT for Monitoring of Ipilimumab Therapy in Patients with Metastatic Melanoma.

Ito K, Teng R, Schöder H, Humm JL, Ni A, Michaud L, Nakajima R, Yamashita R, Wolchok JD, Weber WA.

J Nucl Med. 2019 Mar;60(3):335-341. doi: 10.2967/jnumed.118.213652. Epub 2018 Nov 9.

28.

Biodistribution and radiation dose estimates for 68Ga-DOTA-JR11 in patients with metastatic neuroendocrine tumors.

Krebs S, Pandit-Taskar N, Reidy D, Beattie BJ, Lyashchenko SK, Lewis JS, Bodei L, Weber WA, O'Donoghue JA.

Eur J Nucl Med Mol Imaging. 2019 Mar;46(3):677-685. doi: 10.1007/s00259-018-4193-y. Epub 2018 Oct 29.

PMID:
30374529
29.

Galectin-3 Targeting in Thyroid Orthotopic Tumors Opens New Ways to Characterize Thyroid Cancer.

De Rose F, Braeuer M, Braesch-Andersen S, Otto AM, Steiger K, Reder S, Mall S, Nekolla S, Schwaiger M, Weber WA, Bartolazzi A, D'Alessandria C.

J Nucl Med. 2019 Jun;60(6):770-776. doi: 10.2967/jnumed.118.219105. Epub 2018 Oct 25.

30.

Correction to: Effect of radiochemotherapy on T2* MRI in HNSCC and its relation to FMISO PET derived hypoxia and FDG PET.

Wiedenmann N, Bunea H, Rischke HC, Bunea A, Majerus L, Bielak L, Protopopov A, Ludwig U, Büchert M, Stoykow C, Nicolay NH, Weber WA, Mix M, Meyer PT, Hennig J, Bock M, Grosu AL.

Radiat Oncol. 2018 Sep 21;13(1):183. doi: 10.1186/s13014-018-1134-7.

31.

Diffusion-weighted MRI and ADC versus FET-PET and GdT1w-MRI for gross tumor volume (GTV) delineation in re-irradiation of recurrent glioblastoma.

Popp I, Bott S, Mix M, Oehlke O, Schimek-Jasch T, Nieder C, Nestle U, Bock M, Yuh WTC, Meyer PT, Weber WA, Urbach H, Mader I, Grosu AL.

Radiother Oncol. 2019 Jan;130:121-131. doi: 10.1016/j.radonc.2018.08.019. Epub 2018 Sep 12.

PMID:
30219612
32.

Effect of radiochemotherapy on T2* MRI in HNSCC and its relation to FMISO PET derived hypoxia and FDG PET.

Wiedenmann N, Bunea H, Rischke HC, Bunea A, Majerus L, Bielak L, Protopopov A, Ludwig U, Büchert M, Stoykow C, Nicolay NH, Weber WA, Mix M, Meyer PT, Hennig J, Bock M, Grosu AL.

Radiat Oncol. 2018 Aug 29;13(1):159. doi: 10.1186/s13014-018-1103-1. Erratum in: Radiat Oncol. 2018 Sep 21;13(1):183.

33.

Positron-emission tomography imaging in urological oncology: Current aspects and developments.

Rauscher I, Eiber M, Weber WA, Gschwend JE, Horn T, Maurer T.

Int J Urol. 2018 Nov;25(11):912-921. doi: 10.1111/iju.13779. Epub 2018 Aug 13. Review.

34.

Detection Efficacy of 18F-PSMA-1007 PET/CT in 251 Patients with Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy.

Giesel FL, Knorr K, Spohn F, Will L, Maurer T, Flechsig P, Neels O, Schiller K, Amaral H, Weber WA, Haberkorn U, Schwaiger M, Kratochwil C, Choyke P, Kramer V, Kopka K, Eiber M.

J Nucl Med. 2019 Mar;60(3):362-368. doi: 10.2967/jnumed.118.212233. Epub 2018 Jul 24.

35.

Discriminating radiation injury from recurrent tumor with [18F]PARPi and amino acid PET in mouse models.

Donabedian PL, Kossatz S, Engelbach JA, Jannetti SA, Carney B, Young RJ, Weber WA, Garbow JR, Reiner T.

EJNMMI Res. 2018 Jul 4;8(1):59. doi: 10.1186/s13550-018-0399-z.

36.

Discrete patterns of cortical thickness in youth with bipolar disorder differentially predict treatment response to quetiapine but not lithium.

Zhang W, Xiao Y, Sun H, Patino LR, Tallman MJ, Weber WA, Adler CM, Klein C, Strawn JR, Nery FG, Gong Q, Sweeney JA, Lui S, DelBello MP.

Neuropsychopharmacology. 2018 Oct;43(11):2256-2263. doi: 10.1038/s41386-018-0120-y. Epub 2018 Jun 18.

37.

Antibody with Infinite Affinity for In Vivo Tracking of Genetically Engineered Lymphocytes.

Krebs S, Ahad A, Carter LM, Eyquem J, Brand C, Bell M, Ponomarev V, Reiner T, Meares CF, Gottschalk S, Sadelain M, Larson SM, Weber WA.

J Nucl Med. 2018 Dec;59(12):1894-1900. doi: 10.2967/jnumed.118.208041. Epub 2018 Jun 14.

38.

11C-Choline Pharmacokinetics in Recurrent Prostate Cancer.

Grkovski M, Gharzeddine K, Sawan P, Schöder H, Michaud L, Weber WA, Humm JL.

J Nucl Med. 2018 Nov;59(11):1672-1678. doi: 10.2967/jnumed.118.210088. Epub 2018 Apr 6.

39.

Reproducibility and Repeatability of Semiquantitative 18F-Fluorodihydrotestosterone Uptake Metrics in Castration-Resistant Prostate Cancer Metastases: A Prospective Multicenter Study.

Vargas HA, Kramer GM, Scott AM, Weickhardt A, Meier AA, Parada N, Beattie BJ, Humm JL, Staton KD, Zanzonico PB, Lyashchenko SK, Lewis JS, Yaqub M, Sosa RE, van den Eertwegh AJ, Davis ID, Ackermann U, Pathmaraj K, Schuit RC, Windhorst AD, Chua S, Weber WA, Larson SM, Scher HI, Lammertsma AA, Hoekstra OS, Morris MJ.

J Nucl Med. 2018 Oct;59(10):1516-1523. doi: 10.2967/jnumed.117.206490. Epub 2018 Apr 6.

40.

Somatostatin Receptor Imaging of Neuroendocrine Tumors: From Agonists to Antagonists.

Bodei L, Weber WA.

J Nucl Med. 2018 Jun;59(6):907-908. doi: 10.2967/jnumed.117.205161. Epub 2018 Mar 30. No abstract available.

41.

Direct Imaging of Drug Distribution and Target Engagement of the PARP Inhibitor Rucaparib.

Kossatz S, Carney B, Farley C, Weber WA, Drain CM, Reiner T.

J Nucl Med. 2018 Aug;59(8):1316-1320. doi: 10.2967/jnumed.117.205765. Epub 2018 Mar 23.

42.

PARP-1-Targeted Radiotherapy in Mouse Models of Glioblastoma.

Jannetti SA, Carlucci G, Carney B, Kossatz S, Shenker L, Carter LM, Salinas B, Brand C, Sadique A, Donabedian PL, Cunanan KM, Gönen M, Ponomarev V, Zeglis BM, Souweidane MM, Lewis JS, Weber WA, Humm JL, Reiner T.

J Nucl Med. 2018 Aug;59(8):1225-1233. doi: 10.2967/jnumed.117.205054. Epub 2018 Mar 23.

43.

Synthesis and Evaluation of a Novel 64Cu- and 67Ga-Labeled Neurokinin 1 Receptor Antagonist for in Vivo Targeting of NK1R-Positive Tumor Xenografts.

Zhang H, Kanduluru AK, Desai P, Ahad A, Carlin S, Tandon N, Weber WA, Low PS.

Bioconjug Chem. 2018 Apr 18;29(4):1319-1326. doi: 10.1021/acs.bioconjchem.8b00063. Epub 2018 Feb 27.

PMID:
29466853
44.

Target engagement imaging of PARP inhibitors in small-cell lung cancer.

Carney B, Kossatz S, Lok BH, Schneeberger V, Gangangari KK, Pillarsetty NVK, Weber WA, Rudin CM, Poirier JT, Reiner T.

Nat Commun. 2018 Jan 12;9(1):176. doi: 10.1038/s41467-017-02096-w.

45.

Targeting CXCR4 with [68Ga]Pentixafor: a suitable theranostic approach in pleural mesothelioma?

Lapa C, Kircher S, Schirbel A, Rosenwald A, Kropf S, Pelzer T, Walles T, Buck AK, Weber WA, Wester HJ, Herrmann K, Lückerath K.

Oncotarget. 2017 May 27;8(57):96732-96737. doi: 10.18632/oncotarget.18235. eCollection 2017 Nov 14.

46.

Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed miTNM Classification for the Interpretation of PSMA-Ligand PET/CT.

Eiber M, Herrmann K, Calais J, Hadaschik B, Giesel FL, Hartenbach M, Hope T, Reiter R, Maurer T, Weber WA, Fendler WP.

J Nucl Med. 2018 Mar;59(3):469-478. doi: 10.2967/jnumed.117.198119. Epub 2017 Nov 9. Erratum in: J Nucl Med. 2018 Jun;59(6):992.

47.

Positron Emission Tomography/Computed Tomography-Based Assessments of Androgen Receptor Expression and Glycolytic Activity as a Prognostic Biomarker for Metastatic Castration-Resistant Prostate Cancer.

Fox JJ, Gavane SC, Blanc-Autran E, Nehmeh S, Gönen M, Beattie B, Vargas HA, Schöder H, Humm JL, Fine SW, Lewis JS, Solomon SB, Osborne JR, Veach D, Sawyers CL, Weber WA, Scher HI, Morris MJ, Larson SM.

JAMA Oncol. 2018 Feb 1;4(2):217-224. doi: 10.1001/jamaoncol.2017.3588.

48.

Theranostic Concepts: More Than Just a Fashion Trend-Introduction and Overview.

Herrmann K, Larson SM, Weber WA.

J Nucl Med. 2017 Sep;58(Suppl 2):1S-2S. doi: 10.2967/jnumed.117.199570. No abstract available.

49.

Targeted PET imaging strategy to differentiate malignant from inflamed lymph nodes in diffuse large B-cell lymphoma.

Tang J, Salloum D, Carney B, Brand C, Kossatz S, Sadique A, Lewis JS, Weber WA, Wendel HG, Reiner T.

Proc Natl Acad Sci U S A. 2017 Sep 5;114(36):E7441-E7449. doi: 10.1073/pnas.1705013114. Epub 2017 Aug 21.

50.

Biodistribution and Dosimetry of 18F-Meta-Fluorobenzylguanidine: A First-in-Human PET/CT Imaging Study of Patients with Neuroendocrine Malignancies.

Pandit-Taskar N, Zanzonico P, Staton KD, Carrasquillo JA, Reidy-Lagunes D, Lyashchenko S, Burnazi E, Zhang H, Lewis JS, Blasberg R, Larson SM, Weber WA, Modak S.

J Nucl Med. 2018 Jan;59(1):147-153. doi: 10.2967/jnumed.117.193169. Epub 2017 Jul 13.

Supplemental Content

Loading ...
Support Center